The cytokine storm and COVID‐19
B Hu, S Huang, L Yin - Journal of medical virology, 2021 - Wiley Online Library
Abstract Coronavirus disease 2019 (COVID‐19), which began in Wuhan, China, in
December 2019, has caused a large global pandemic and poses a serious threat to public …
December 2019, has caused a large global pandemic and poses a serious threat to public …
Recognizing COVID-19–related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management
B Siripanthong, S Nazarian, D Muser, R Deo… - Heart rhythm, 2020 - Elsevier
Human coronavirus-associated myocarditis is known, and a number of coronavirus disease
19 (COVID-19)–related myocarditis cases have been reported. The pathophysiology of …
19 (COVID-19)–related myocarditis cases have been reported. The pathophysiology of …
Drug treatments for covid-19: living systematic review and network meta-analysis
Objective To compare the effects of treatments for coronavirus disease 2019 (covid-19).
Design Living systematic review and network meta-analysis. Data sources WHO covid-19 …
Design Living systematic review and network meta-analysis. Data sources WHO covid-19 …
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions
The coronavirus disease-19 pandemic (COVID-19), which appeared in China in December
2019 and rapidly spread throughout the world, has forced clinicians and scientists to take up …
2019 and rapidly spread throughout the world, has forced clinicians and scientists to take up …
An update on current therapeutic drugs treating COVID-19
The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented …
respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented …
Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19
Background Despite limited and conflicting evidence, hydroxychloroquine, alone or in
combination with azithromycin, is widely used in COVID-19 therapy. Methods We performed …
combination with azithromycin, is widely used in COVID-19 therapy. Methods We performed …
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician …
M Gianfrancesco, KL Hyrich, S Al-Adely… - Annals of the …, 2020 - ard.bmj.com
Objectives COVID-19 outcomes in people with rheumatic diseases remain poorly
understood. The aim was to examine demographic and clinical factors associated with …
understood. The aim was to examine demographic and clinical factors associated with …
Mild or moderate Covid-19
Key Clinical Points Mild or Moderate Covid-19 Covid-19 has a range of clinical
manifestations, including cough, fever, myalgias, gastrointestinal symptoms, and anosmia …
manifestations, including cough, fever, myalgias, gastrointestinal symptoms, and anosmia …
QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin
E Chorin, L Wadhwani, S Magnani, M Dai, E Shulman… - Heart rhythm, 2020 - Elsevier
Background There is no known effective therapy for patients with coronavirus disease 2019
(COVID-19). Initial reports suggesting the potential benefit of hydroxychloroquine …
(COVID-19). Initial reports suggesting the potential benefit of hydroxychloroquine …
Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review
AV Hernandez, YM Roman, V Pasupuleti… - Annals of internal …, 2020 - acpjournals.org
An update is available for this article. Background: Hydroxychloroquine and chloroquine
have antiviral effects in vitro against severe acute respiratory syndrome coronavirus 2 …
have antiviral effects in vitro against severe acute respiratory syndrome coronavirus 2 …